All > Acl > California

Parsaclisib for B-Cell Cancers

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
City of Hope National Medical Center, Duarte, CAB-Cell CancersParsaclisib - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is for people who have already been taking parsaclisib in other studies, and will continue to take it either alone or with other drugs.

Eligible Conditions
  • B Cell Cancers

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Copanlisib
1
Parsaclisib
1
Ruxolitinib

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Through study completion, an average of 5 years

Year 5
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Copanlisib
1
Parsaclisib
1
Ruxolitinib

Side Effects for

Parsaclisib 15 mg QD + R-ICE
100%Anaemia
75%Neutropenia
75%Thrombocytopenia
50%Fluid overload
50%Headache
50%Hypokalaemia
50%Alopecia
50%Dizziness
25%Supraventricular tachycardia
25%Tinnitus
25%Visual perseveration
25%Oral pain
25%Respiratory syncytial virus test positive
25%Sinus tachycardia
25%Tachycardia
25%Wound infection bacterial
25%Wound infection pseudomonas
25%White blood cell count decreased
25%Constipation
25%Pruritus
25%Atrial flutter
25%Arthralgia
25%Chills
25%Dermatitis acneiform
25%Influenza
25%Muscle spasms
25%Nasal congestion
25%Nausea
25%Night sweats
25%Oedema peripheral
25%Pyrexia
25%Syncope
25%Dyspnoea
25%Pulmonary oedema
25%Hypertension
25%Febrile neutropenia
25%Dyspnoea exertional
25%Fatigue
25%Rash
25%Cough
25%Palpitations
25%White blood cell count increased
25%Atrial fibrillation
25%Hypomagnesaemia
25%Insomnia
25%Laryngeal inflammation
25%Blood creatinine increased
25%Diarrhoea
25%Decreased appetite
25%Dysuria
25%Eye irritation
25%Muscle twitching
25%Neuropathy peripheral
25%Weight increased
This histogram enumerates side effects from a completed 2021 Phase 1 & 2 trial (NCT02018861) in the Parsaclisib 15 mg QD + R-ICE ARM group. Side effects include: Anaemia with 100%, Neutropenia with 75%, Thrombocytopenia with 75%, Fluid overload with 50%, Headache with 50%.

Trial Design

4 Treatment Groups

parsaclisib + ruxolitinib
1 of 4
parsaclicib + itacitinib
1 of 4
parsaclisib + ibrutinib
1 of 4
parsaclisib
1 of 4

Experimental Treatment

200 Total Participants · 4 Treatment Groups

Primary Treatment: Parsaclisib · No Placebo Group · Phase 2

parsaclisib + ruxolitinib
Drug
Experimental Group · 1 Intervention: parsaclisib + ruxolitinib · Intervention Types: Drug
parsaclicib + itacitinib
Drug
Experimental Group · 1 Intervention: parsaclisib + itacitinib · Intervention Types: Drug
parsaclisib + ibrutinib
Drug
Experimental Group · 1 Intervention: parsaclisib + ibrutinib · Intervention Types: Drug
parsaclisib
Drug
Experimental Group · 1 Intervention: Parsaclisib · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Parsaclisib
Not yet FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 5 years

Who is running the clinical trial?

Incyte CorporationLead Sponsor
323 Previous Clinical Trials
46,821 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

Has the FDA given Parsaclisib its stamp of approval?

"Given the Phase 2 status, our team at Power has evaluated Parsaclisib's safety as a score of 2. Currently, there is some data affirming its security but no studies yet that have proven efficacy." - Anonymous Online Contributor

Unverified Answer

How much healthcare infrastructure is being utilized for this research endeavor?

"At the moment, 26 medical facilities are running this clinical trial. Aside from Long Beach, Kansas City and Seattle, there are 23 other sites in various cities across the nation. For ease of access for participants it is encouraged to select a location closest to you." - Anonymous Online Contributor

Unverified Answer

Is enrollment for the trial still available to interested participants?

"Affirmative. The clinical trial directory hosted on the governmental website highlights that this research has been open for applications since August 3rd 2020 and is currently in search of 200 participants across 26 facilities." - Anonymous Online Contributor

Unverified Answer

What is the current capacity for participants in this medical study?

"To meet the demands of this trial, 200 qualifying patients must be recruited. Incyte Corporation will be handling operations from two locations: Innovative Clinical Research Institute in Long Beach, California and Saint Luke'S Hospital of Kansas City in Missouri." - Anonymous Online Contributor

Unverified Answer

What evidence exists of Parsaclisib being examined in other scientific experiments?

"Currently, there are 39 ongoing clinical trials focused on Parsaclisib; four of them in their final stage. These studies have been established mainly in Rozzano but also span 1280 other locations worldwide." - Anonymous Online Contributor

Unverified Answer

Has this type of experiment been conducted previously or is it a pioneering endeavor?

"Presently, 39 research trials involving Parsaclisib are underway across 137 cities and 28 states. This drug was initially tested in 2013, when Incyte Corporation sponsored a trial with 121 participants that completed Phase 1 of the approval process. Since then, 20 separate studies have been carried out." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top